Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

This study has been completed.
Information provided by:
Seattle Genetics, Inc. Identifier:
First received: December 10, 2004
Last updated: December 17, 2014
Last verified: December 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2007
  Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)